Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke (Review)

Kikuchi,Kiyoshi; Miura,Naoki; Kawahara,Ko-Ichi; Murai,Yoshinaka; Morioka,Motohiro; Lapchak,Paul  A.; Tanaka,Eiichiro

doi:10.3892/br.2012.7

Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke (Review)

Authors:
- Kiyoshi Kikuchi
- Naoki Miura
- Ko-Ichi Kawahara
- Yoshinaka Murai
- Motohiro Morioka
- Paul A. Lapchak
- Eiichiro Tanaka
View Affiliations

Affiliations: Department of Neurology, Cedars-Sinai Medical Center, Davis Research Building, Los Angeles, CA 90048, USA, Laboratory of Functional Foods, Department of Biomedical Engineering, Osaka Institute of Technology, Osaka 535-8585, Japan , Department of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890‑8520, Japan, Department of Physiology, Kurume University School of Medicine, Fukuoka 830-0011, Japan, Department of Neurosurgery, Kurume University School of Medicine, Fukuoka 830-0011, Japan
Published online on: August 29, 2012 https://doi.org/10.3892/br.2012.7
Pages: 7-12

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute ischemic stroke (AIS) is a major cause of morbidity and mortality in the aging population worldwide. Alteplase, a recombinant tissue plasminogen activator, is the only Food and Drug Administration-approved thrombolytic agent for the treatment of AIS. Only 2-5% of patients with stroke receive thrombolytic treatment, mainly due to delay in reaching the hospital. Edaravone is a free radical scavenger marketed in Japan to treat patients with AIS, who present within 24 h of the onset of symptoms. When used in combination with alteplase, edaravone may have three useful effects: enhancement of early recanalization, inhibition of alteplase‑induced hemorrhagic transformation and extension of the therapeutic time window for alteplase. This is the first review of the literature evaluating the clinical efficacy of edaravone, aiming to clarify whether edaravone should be further evaluated for clinical use worldwide. This review covers both clinical and experimental studies conducted between 1994 and 2012. Edaravone is a potentially useful neurovascular protective agent, used in combination with thrombolytic agents to treat >15 million patients devastated by stroke worldwide annually. Additional clinical studies are necessary to verify the efficacy of edaravone when used in combination with a thrombolytic agent.

View Figures

View References

1.	Ingall T: Stroke - incidence, mortality, morbidity and risk. J Insur Med. 36:143–152. 2004.
2.	Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Eng J Med. 333:1581–1587. 1995. View Article : Google Scholar : PubMed/NCBI
3.	European Stroke Organisation Exective Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 25:457–507. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Adams HP Jr, del Zoppo G, Alberts MJ, et al: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 115:e478–e534. 2007.
5.	Cheng T, Petraglia AL, Li Z, et al: Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med. 12:1278–1285. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Nicole O, Docagne F, Ali C, et al: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 7:59–64. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A and Nadzam DM: Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 61:346–350. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Lichtman JH, Watanabe E, Allen NB, Jones SB, Dostal J and Goldstein LB: Hospital arrival time and intravenous t-PA use in US Academic Medical Centers, 2001–2004. Stroke. 40:3845–3850. 2009.PubMed/NCBI
9.	Reeves MJ, Broderick JP, Frankel M, et al: The Paul Coverdell National Acute Stroke Registry: initial results from four prototypes. Am J Prev Med. 31:S202–S209. 2006. View Article : Google Scholar : PubMed/NCBI
10.	California Acute Stroke Pilot Registry (CASPR) Investigators: Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 64:654–659. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Albers GW and Olivot JM: Intravenous alteplase for ischaemic stroke. Lancet. 369:249–250. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Wahlgren N, Ahmed N, Davalos A, et al: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 369:275–282. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Nakagawara J, Minematsu K, Okada Y, et al: Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 41:1984–1989. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Kimura K, Aoki J, Sakamoto Y, et al: Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients - a preliminary study. J Neurol Sci. 313:132–136. 2012. View Article : Google Scholar : PubMed/NCBI
15.	No authors listed:. Neuroprotection: the end of an era? Lancet. 368:15482006. View Article : Google Scholar : PubMed/NCBI
16.	Lapchak PA and Zivin JA: The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol. 215:95–100. 2009. View Article : Google Scholar
17.	Lees KR, Zivin JA, Ashwood T, et al: NXY-059 for acute ischemic stroke. N Eng J Med. 354:588–600. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Shuaib A, Lees KR, Lyden P, et al: NXY-059 for the treatment of acute ischemic stroke. N Eng J Med. 357:562–571. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Lapchak PA: A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 11:1753–1763. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Wang CX and Shuaib A: Neuroprotective effects of free radical scavengers in stroke. Drugs Aging. 24:537–546. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Adams HP Jr, del Zoppo G, Alberts MJ, et al: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 38:1655–1711. 2007.
22.	Watanabe T, Yuki S, Egawa M and Nishi H: Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 268:1597–1604. 1994.PubMed/NCBI
23.	Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito KI and Kogure K: Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res. 762:240–242. 1997. View Article : Google Scholar
24.	Lapchak PA and Araujo DM: Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. CNS Drug Rev. 9:253–262. 2003. View Article : Google Scholar : PubMed/NCBI
25.	Watanabe T, Tahara M and Todo S: The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther. 26:101–114. 2008. View Article : Google Scholar : PubMed/NCBI
26.	Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N and Tada N: Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev. 12:9–20. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Kikuchi K, Kawahara K, Tancharoen S, et al: The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther. 329:865–874. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Kikuchi K, Tancharoen S, Matsuda F, et al: Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem Biophys Res Commun. 390:1121–1125. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Tanaka E, Niiyama S, Sato S, Yamada A and Higashi H: Arachidonic acid metabolites contribute to the irreversible depolarization induced by in vitro ischemia. J Neurophysiol. 90:3213–3223. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Kikuchi K, Kawahara K, Miyagi N, et al: Edaravone: a new therapeutic approach for the treatment of acute stroke. Med Hypotheses. 75:583–585. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Kikuchi K, Uchikado H, Miyagi N, et al: Beyond neurological disease: New targets for edaravone (Review). Int J Mol Med. 28:899–906. 2011.PubMed/NCBI
32.	Kikuchi K, Takeshige N, Miura N, et al: Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review). Exp Ther Med. 3:3–8. 2012.PubMed/NCBI
33.	Kikuchi K, Kawahara K, Uchikado H, et al: Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction (Review). Exp Ther Med. 2:771–775. 2011.PubMed/NCBI
34.	Kikuchi K, Miura N, Morimoto Y, et al: Beneficial effects of the free radical scavenger edaravone (Radicut) in neurologic diseases. J Neurol Neurophysiol. 1:1–5. 2011. View Article : Google Scholar
35.	Edaravone Acute Infarction Study Group: Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 15:222–229. 2003. View Article : Google Scholar : PubMed/NCBI
36.	Naritomi H, Moriwaki H, Metoki N, et al: Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. Drugs RD. 10:155–163. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Shinohara Y, Saito I, Kobayashi S and Uchiyama S: Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis. 27:485–492. 2009. View Article : Google Scholar
38.	Unno Y, Katayama M and Shimizu H: Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy. Clin Drug Investig. 30:143–155. 2010. View Article : Google Scholar
39.	Wahlgren N, Ahmed N, Davalos A, et al: Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 372:1303–1309. 2008.
40.	Hacke W, Kaste M, Bluhmki E, et al: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Eng J Med. 359:1317–1329. 2008. View Article : Google Scholar
41.	Wardlaw JM, Murray V, Berge E, et al: Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 379:2364–2372. 2012. View Article : Google Scholar : PubMed/NCBI
42.	Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 28:2109–2118. 1997. View Article : Google Scholar : PubMed/NCBI
43.	Yamashita T, Kamiya T, Deguchi K, et al: Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab. 29:715–725. 2009. View Article : Google Scholar : PubMed/NCBI
44.	Lukic-Panin V, Deguchi K, Yamashita T, et al: Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr Neurovasc Res. 7:319–329. 2010. View Article : Google Scholar
45.	Yagi K, Kitazato KT, Uno M, et al: Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke. 40:626–631. 2009. View Article : Google Scholar : PubMed/NCBI
46.	Zhang W, Sato K, Hayashi T, et al: Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res. 26:342–348. 2004. View Article : Google Scholar : PubMed/NCBI
47.	Kano T, Harada T and Katayama Y: Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. Neurol Res. 27:499–502. 2005. View Article : Google Scholar : PubMed/NCBI
48.	Isahaya K, Yamada K, Yamatoku M, et al: Effects of edaravone, a free radical scavenger, on serum levels of inflammatory biomarkers in acute brain infarction. J Stroke Cerebrovasc Dis. 21:102–107. 2012. View Article : Google Scholar : PubMed/NCBI
49.	Nakamura T, Kuroda Y, Yamashita S, et al: Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke. 39:463–469. 2008. View Article : Google Scholar : PubMed/NCBI
50.	Kamiya T and Abe K: Future neuroprotective strategies in the post-thrombolysis era - neurovascular unit protection and vascular endothelial protection. Rinsho Shinkeigaku. 51:305–315. 2011.(In Japanese).
51.	Wahlgren N, Ahmed N, Eriksson N, et al: Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke. 39:3316–3322. 2008. View Article : Google Scholar
52.	Yamaguchi T, Mori E, Minematsu K, et al: Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 37:1810–1815. 2006. View Article : Google Scholar : PubMed/NCBI
53.	Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M and Hirano T: Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke. 41:461–465. 2010. View Article : Google Scholar
54.	Eesa M, Schumacher HC, Higashida RT and Meyers PM: Advances in revascularization for acute ischemic stroke treatment: an update. Expert Rev Neurother. 11:1125–1139. 2011. View Article : Google Scholar : PubMed/NCBI
55.	Frendl A and Csiba L: Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke. Front Neurol. 2:322011.PubMed/NCBI
56.	Tanswell P, Modi N, Combs D and Danays T: Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 41:1229–1245. 2002. View Article : Google Scholar : PubMed/NCBI
57.	Verstraete M: Third-generation thrombolytic drugs. Am J Med. 109:52–58. 2000. View Article : Google Scholar : PubMed/NCBI
58.	Parsons M, Spratt N, Bivard A, et al: A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Eng J Med. 366:1099–1107. 2012. View Article : Google Scholar : PubMed/NCBI
59.	Misra V, El Khoury R, Arora R, et al: Safety of high doses of urokinase and reteplase for acute ischemic stroke. AJNR Am J Neuroraidol. 32:998–1001. 2011. View Article : Google Scholar : PubMed/NCBI
60.	Liberatore GT, Samson A, Bladin C, Schleuning WD and Medcalf RL: Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 34:537–543. 2003. View Article : Google Scholar
61.	Schleuning WD: Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis. 31:118–122. 2001.PubMed/NCBI
62.	Hacke W, Albers G, Al-Rawi Y, et al: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 36:66–73. 2005. View Article : Google Scholar : PubMed/NCBI
63.	Furlan AJ, Eyding D, Albers GW, et al: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 37:1227–1231. 2006. View Article : Google Scholar : PubMed/NCBI
64.	Hacke W, Furlan AJ, Al-Rawi Y, et al: Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 8:141–150. 2009. View Article : Google Scholar
65.	Paciaroni M, Medeiros E and Bogousslavsky J: Desmoteplase. Expert Opin Biol Ther. 9:773–778. 2009. View Article : Google Scholar